Improvements in excessive daytime sleepiness were also observed in individuals with narcolepsy type 2, indicating that OX2R-selective agonists could also provide therapy for sleep disorders that involve partial or no impairment of the orexin system. This evidence concerns the gene HCRTR2 and narcolepsy without cataplexy.